Page last updated: 2024-10-25

deferoxamine and Systemic Inflammatory Response Syndrome

deferoxamine has been researched along with Systemic Inflammatory Response Syndrome in 1 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever

Research Excerpts

ExcerptRelevanceReference
"We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)."7.78Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012)
"We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)."3.78Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vlahakos, D1
Arkadopoulos, N1
Kostopanagiotou, G1
Siasiakou, S1
Kaklamanis, L1
Degiannis, D1
Demonakou, M1
Smyrniotis, V1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550]Phase 1/Phase 250 participants (Anticipated)Interventional2020-04-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for deferoxamine and Systemic Inflammatory Response Syndrome

ArticleYear
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.
    Artificial organs, 2012, Volume: 36, Issue:4

    Topics: Acute Disease; Acute Kidney Injury; Animals; Apoptosis; Deferoxamine; Female; Interleukin-6; Ischemi

2012